- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe active juvenile idiopathic arthritis (JIA)
- Meeting Date: March 2020
- Public Summary Document (PSD) March 2020 PBAC Meeting - (PDF 831KB)
- Public Summary Document (PSD) March 2020 PBAC Meeting - (Word 167KB)
Tocilizumab – March 2020
Tocilizumab: Injection 162 mg in 0.9 ml single use pre-filled pen, Injection 162 mg in 0.9 ml single use pre-filled syringe; Actemra®
Last updated
3 July 2020